Clinical research underpins the future of medicine, but the way trials are run today remains mired in outdated practices. The human and financial cost of this failure is staggering. Every delay, every missed enrolment target, and every redundant administrative step adds up. The result is slower access to life‑saving therapies and ballooning budgets that burden sponsors, healthcare systems, and ultimately, patients.
Too many trials are designed with protocols that are scientifically brilliant but humanly impractical, leading to high patient dropout rates. The scientific objectives are, of course, non-negotiable for proving a drug’s safety and efficacy. The path forward is to balance those objectives with the patient’s reality by integrating flexible, decentralised trial components to reduce the burden of participation.
Reactive, late-stage protocol amendments are a predictable and costly drain on resources for nearly every study. While these changes are usually well-intentioned attempts to improve a trial’s viability, the time to make them is at the start. We must get better at pressure-testing protocols against real-world data and involving sites in the design phase, making these amendments the rare exception, not the rule.
The most sobering fact is that every inefficiency in trial operations is paid for by someone: sponsors, taxpayers, and/or the patients themselves. Addressing these flaws is no longer optional. It is essential.
Hidden Costs of Clinical Trial Inefficiencies
Clinical trial inefficiencies start early and compound over time. From protocol design through recruitment and data collection, outdated methods slow everything down. Manual data entry and fragmented systems lead to duplication and errors that waste weeks. Complex protocols designed without patient input create logistical nightmares for sites and participants alike. This not only drives up operational costs but also reduces trial retention and delays results.
The financial burden of clinical trial inefficiencies is significant and increases exponentially with each delay. A mid‑sized phase three trial can cost hundreds of millions of pounds to execute. Studies report that delays in recruitment alone can push costs up by tens of thousands per day. More alarming is that roughly 80% of trials fail to meet original recruitment timelines. When enrolment lags, entire development pipelines stall.
The ripple effects are rarely discussed outside industry circles. Regulatory submissions get delayed. Manufacturing schedules shift, wasting resources on products that cannot yet reach patients. Payers and health systems, already under strain, face prolonged uncertainty over treatment availability and pricing. At the same time, patients remain stuck with limited options, waiting for studies that may already be years behind schedule.
Why Clinical Trial Screening Fails Patients
Clinical trial screening is supposed to be straightforward. Identify who qualifies, confirm eligibility, and move forward. In reality, this process is riddled with inefficiencies. Many sites rely on manual chart reviews or outdated software that fails to integrate with hospital records. As a result, promising candidates are overlooked, and staff spend valuable time chasing incomplete information.
The impact of flawed screening goes beyond wasted labour. Inconsistent processes often lead to mismatches between trial requirements and patient realities, which contributes to higher dropout rates later in the study. Poor screening practices also limit diversity by inadvertently excluding underrepresented groups who could benefit most from participation. This lack of inclusion skews data and delays approval for treatments that should serve broader populations.
One promising shift is the rise of automated pre‑screening tools integrated with electronic health records. Trials using these systems have reported recruitment boosts of up to 30% without additional site staff. Wider adoption of these methods could transform patient access and cut months off trial timelines.
What makes modern clinical trial screening tools so effective is their ability to continuously update. As new data enters patient records, eligibility checks can run in real time. This means patients no longer slip through the cracks simply because their records were reviewed months ago. When combined with targeted digital outreach, this approach not only accelerates recruitment but also reduces the frustration patients often feel when they express interest in a study only to learn they do not qualify.
The Human Cost Nobody Wants to Acknowledge
Behind every statistic is a patient waiting for hope. Delays in trial timelines mean that individuals living with chronic or terminal conditions face prolonged uncertainty. Families rearrange their lives around study visits, only to be let down by cancellations or poor communication. Site staff, stretched thin by archaic systems, burn out and leave the field, further fuelling delays.
These problems do not exist in isolation. Operational flaws at one stage of the trial cascade into every other stage. A poorly designed screening process leads to mismatched participants, which increases protocol deviations, which in turn drives up monitoring costs and slows analysis. It is a domino effect that undermines the entire research ecosystem.
The psychological toll on patients is equally damaging. Many enter trials with cautious optimism, hoping for a therapy that might ease their condition or extend their life. When systems fail them, that hope erodes. Over time, mistrust grows, making recruitment for future studies even harder. Communities already hesitant to engage with research can become permanently alienated, worsening disparities in trial participation.
Fixing What Is Broken Starts With Priorities
Reforming trial operations requires more than new technology. It demands a cultural shift that prioritises simplicity, transparency, and patient experience at every stage. Protocols must be co‑designed with patient input to ensure they are realistic. Sites need centralised tools that integrate recruitment, screening, and data capture into a single workflow. Most importantly, performance metrics must evolve. Success should be measured not just by timelines met but by participant satisfaction and representativeness of the recruited population.
The good news is that solutions already exist. Hybrid trial designs, remote monitoring, and centralised data systems have proven their worth in recent years. The barrier is no longer feasibility but willingness to change entrenched processes. Sponsors and regulators who commit to modernisation stand to save millions while delivering therapies faster to the people who need them.
Reform also opens the door to greater collaboration. When data flows more freely between sponsors, sites, and patients, bottlenecks disappear. Recruitment becomes proactive rather than reactive. Screening evolves from a static checklist into a dynamic process that learns and improves with each study. This is how the industry can break free from decades‑old inefficiencies and meet the rising expectations of both patients and payers.
We are at a crossroads. Either the industry continues absorbing the rising cost of inefficiency or it confronts the problem head‑on and redesigns how research is conducted. Patients cannot afford more delays. Neither can sponsors or healthcare systems.
Let’s work together to balance scientific objectives with patient reality by integrating flexible, decentralised trial components that reduce patient burden.
Keith Berelowitz | Founder & CEO
Keith Berelowitz is the Founder of pRxEngage, a company redefining patient engagement and retention in clinical trials using living experience, proven methods, and AI.
